Therapeutic Silencing of Bcl-2 by Systemically Administered siRNA Nanotherapeutics Inhibits Tumor Growth by Autophagy and Apoptosis and Enhances the Efficacy of Chemotherapy in Orthotopic Xenograft Models of ER (−) and ER (+) Breast Cancer

Bcl-2 is overexpressed in about a half of human cancers and 50–70% of breast cancer patients, thereby conferring resistance to conventional therapies and making it an excellent therapeutic target. Small interfering RNA (siRNA) offers novel and powerful tools for specific gene silencing and molecular...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ibrahim Tekedereli, S Neslihan Alpay, Ugur Akar, Erkan Yuca, Cristian Ayugo-Rodriguez, He-Dong Han, Anil K Sood, Gabriel Lopez-Berestein, Bulent Ozpolat
Format: Artigo
Jezik:Inglês
Izdano: Elsevier 2013-01-01
Serija:Molecular Therapy: Nucleic Acids
Teme:
apoptosis
autophagy
Bcl-2
breast cancer
chemotherapy
estrogen receptor
gene silencing
liposome
nanoparticles
nanotherapeutics
programmed cell deathsiRNA
Online pristup:http://www.sciencedirect.com/science/article/pii/S2162253116301780
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items